期刊文献+

扩散加权成像表观扩散系数值与乳腺癌患者半乳糖凝集素-3、p53蛋白关系及预测TP化疗效果

Relationship between ADC values in DWI imaging and Gal-3 and p53 protein in breast cancer patients and prediction of TP chemotherapy effect
下载PDF
导出
摘要 目的探讨扩散加权成像(DWI)表观扩散系数(ADC)值与乳腺癌患者半乳糖凝集素-3(Gal-3)、p53蛋白关系及预测TP化疗(多西他赛+卡铂)效果。方法选取2019年10月—2021年10月承德医学院附属医院收治的143例乳腺癌(研究组)、72例乳腺良性肿瘤(良性组)及75例健康体检者(健康组)DWI参数[计算表观弥散系数最小值(ADCmin)、表观扩散系数平均值(ADCmean)]及其与组织Gal-3、p53蛋白相关性,绘制受试者工作曲线(ROC),分析DWI参数预测TP化疗效果。结果研究组ADCmin、ADCmean低于良性组、健康组,且良性组低于健康组(P<0.05)。不同肿瘤直径、病理分级、分化程度、Gal-3、p53蛋白患者ADCmin、ADCmean比较,差异有统计学意义(P<0.05)。ADCmin、ADCmean与肿瘤直径、病理分级、分化程度、Gal-3、p53蛋白呈负相关(P<0.05)。化疗后有效患者ADCmin、ADCmean及差值大于无效患者(P<0.05)。绘制ROC曲线显示,ADCmin、ADCmean差值预测乳腺癌患者TP化疗效果的AUC分别为0.769(95%CI:0.692~0.836)、0.726(95%CI:0.645~0.797)。结论DWI参数与乳腺癌患者Gal-3、p53蛋白呈负相关,且对TP化疗效果具有一定预测价值。 Objective To investigate the relationship between apparent diffusion coefficient(ADC)value of diffusion-weighted imaging(DWI)and galactose lectin-3(Gal-3)and p53 protein in breast cancer patients,and to predict the effect of TP chemotherapy(docetaxel+carboplatin).Methods A total of 143 cases of breast cancer(study group),72 cases of benign breast tumors(benign group)and 75 cases of healthy physical examination subjects(healthy group)were selected from the Affiliated Hospital of Chengde Medical College from October 2019 to October 2021.DWI parameters[calculatedADCmin,ADCmean]and their correlation with tissue Gal-3 and p53 proteins were recorded,and receiver operating curve(ROC)was plotted to analyze DWI parameters to predict the chemotherapy effect of TP.Results The ADCmin and ADCmean of the study group were lower than those of the benign group and the healthy group,and the benign group was lower than the healthy group(P<0.05).There were significant differences in ADCmin and ADCmean among patients with different tumor diameter,pathological grade,differentiation degree,Gal-3 and p53 protein(P<0.05).ADCmin and ADCmean were negatively correlated with tumor diameter,pathological grade,differentiation degree,Gal-3 protein and p53 protein(P<0.05).After chemotherapy,the ADCmin,ADCmean and the difference were higher in effective patients than in ineffective patients(P<0.05).The ROC curve showed that the AUC of ADCmin and ADCmean difference in predicting the chemotherapy effect of TP in breast cancer patients was 0.769(95%CI:0.692-0.836)and 0.726(95%CI:0.645-0.797),respectively.Conclusion DWI parameters are negatively correlated with Gal-3 and p53 proteins in breast cancer patients,and have certain predictive value for the chemotherapy effect of TP.
作者 佟颖 米楠 张荣 张斌 邢千超 王爱辉 TONG Ying;MI Nan;ZHANG Rong;ZHANG Bin;XING Qianchao;WANG Aihui(Radiology Department,The Affiliated Hospital of Chengde Medical University,Chengde 067000,Hebei,China;Medical Equipment Division,The Affiliated Hospital of Chengde Medical University,Chengde 067000,Hebei,China;Department of Nuclear Medicine,The Affiliated Hospital of Chengde Medical University,Chengde 067000,Hebei,China;School of Nursing,Chengde Medical College,Chengde 067000,Hebei,China;Department of Orthopaedics,The 964th Hospital,Changchun 130000,Jilin,China)
出处 《医学研究与战创伤救治》 CAS 北大核心 2023年第12期1272-1276,共5页 Journal of Medical Research & Combat Trauma Care
基金 河北省医学科研课题计划(20200389)。
关键词 乳腺癌 DWI参数 GAL-3 P53蛋白 TP化疗方案 breast cancer DWI parameters Gal-3 p53 protein TP chemotherapy regimen
  • 相关文献

参考文献14

二级参考文献185

  • 1刘慧宇,王贤明,王金生.全数字化钼靶X线摄影、彩色多普勒超声和磁共振成像对乳腺肿瘤病情诊断的作用[J].中国急救医学,2018,38(A01):258-259. 被引量:10
  • 2沈镇宙,宋三泰,张斌,邵志敏,陆劲松.中国绝经前女性乳腺癌患者辅助治疗后绝经判断标准及芳香化酶临床应用共识(草案修正案)[J].中国癌症杂志,2011,21(5):418-420. 被引量:19
  • 3姜涛,姜辉,宋希双,李宪承,李泉林.前列腺癌中P53的表达及其临床意义[J].中华男科学杂志,2005,11(6):448-451. 被引量:11
  • 4FAN L, STRASSER-WEIPPL K, LI J J, et al. Breast cancer in China [J]. Lancet Oncol, 2014, 15(7): e279-289. 被引量:1
  • 5Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials [ J ] . Lancet, 2005, 365(9472): 1687-1717. 被引量:1
  • 6DAVIES C, PAN H, GODWIN J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breastcancer: ATLAS, a randomised trial [ J ] . Lancet, 2013, 381(9869): 805-816. 被引量:1
  • 7GRAY R G, REA D, HANDLEY K, et al. aTTom: long term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6 953 women with early breast cancer [ J ] . J Clin Oncol, 2013, 31(18): 2631-2632. 被引量:1
  • 8CUZICK J, AMBROISINE L, DAVIDSON N, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor- positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials [ J ] . Lancet, 2007, 369(9574): 1711-1723. 被引量:1
  • 9GOEL S, SHARMA R, HAMILTON A, et al. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women [ J ] . Cochrane Database Syst Rev, 2009, 7(4): CD004562. 被引量:1
  • 10FRANCIS P A, REGAN M M, FLEMING G F, et al. Adjuvant ovarian suppression in premenopausal breast cancer [J]. N Engl ] Ned, 2015, 372(5): 436-446. 被引量:1

共引文献190

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部